Aurobindo Pharma subsidiary receives USFDA’s Establishment Inspection Report; stock rises over 4%

Aurobindo Pharma Ltd has informed the stock exchanges that the company’s wholly-owned subsidiary APL Healthcare Ltd. has received establishment inspection report (EIR) from the USFDA, classifying its manufacturing facility at Tirupati, Andhra Pradesh, as ‘voluntary action indicated’ (VAI).

The US FDA conducted an inspection at the company’s unit situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, from September 13 to September 19, 2023.

Aurobindo Pharma stock traded at ₹1,076.90 on the NSE, up by 4.26 per cent as of 1:06 pm on Wednesday.

COMMENT NOW

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.

Aurobindo Pharma subsidiary receives USFDA’s Establishment Inspection Report; stock rises over 4%

The US FDA inspected Aurobindo Pharma’s Andhra Pradesh unit from Sept 13 to 19, 2023

You might also like

You might also like

Comments

Aurobindo Pharma subsidiary receives USFDA’s Establishment Inspection Report; stock rises over 4%

The US FDA inspected Aurobindo Pharma’s Andhra Pradesh unit from Sept 13 to 19, 2023

Related Topics

You might also like

You might also like

Comments